<DOC>
	<DOCNO>NCT00715403</DOCNO>
	<brief_summary>The primary objective trial evaluate long-term safety BIBF 1120 term incidence intensity Adverse Events change safety laboratory parameter . Secondary objective collection safety data ( vital sign ) , efficacy data determination pharmacokinetic characteristic long-term therapy BIBF 1120 .</brief_summary>
	<brief_title>A Phase I/II Open Label Extension Study BIBF 1120 Administered Orally Once Twice Daily Establish Safety , Pharmacokinetics Efficacy Patients With Advanced Solid Tumours Clinical Benefit From Previous Therapy With BIBF 1120</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>1 . Male female patient advance solid tumour complete previous study BIBF 1120 . The patient progression underlie tumour disease unless evidence significant clinical benefit ( e.g . symptom improvement ) treatment BIBF 1120 . 2 . Age 18 year old 3 . Eastern Cooperative Oncology Group ( ECOG , R010787 ) performance score &lt; = 2 4 . Patients must give write informed consent ( must consistent ICHGCP local legislation ) 1 . Time elapse last administration BIBF 1120 previous trial start treatment present trial exceeds four week 2 . Presence drug relate toxicity &gt; grade 2 CTC previous therapy BIBF 1120 presence drug relate continuous toxicity grade 2 seven consecutive day would preclude ongoing chronic therapy BIBF 1120 3 . Active ulcer ( gastrointestinal tract , skin ) 4 . Major injury surgery within past three week incomplete wound heal 5 . Hypersensitivity BIBF 1120 excipients trial drug 6 . Known secondary malignancy require therapy 7 . Active infectious disease 8 . Significant cardiovascular disease ( i.e . uncontrolled severe hypertension , unstable angina pectoris , history myocardial infarction , congestive heart failure &gt; NYHA II ) 9 . Gastrointestinal disorder anticipate interfere resorption study drug 10 . Brain metastasis require therapy 11 . Absolute neutrophil count less 1,500/mm3 12 . Platelet count less 100,000/mm3 13 . Bilirubin great 1.5 mg/dl ( &gt; 26 µmol/L ) 14 . Aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( related liver metastasis great five time upper limit normal ) 15 . Serum creatinine great 2 mg/dl ( &gt; 176 µmol/L ) 16 . Concomitant nononcological disease consider relevant evaluation safety trial drug 17 . Chemo , radio , immunotherapy within past four week prior treatment trial drug 18 . Patients sexually active unwilling use medically acceptable method contraception 19 . Pregnancy lactation 20 . Treatment investigational drug participation another clinical trial within past four week start therapy ( visit 2 ) concomitantly trial ( except previous study BIBF 1120 ) 21 . Patients unable comply protocol 22 . Active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>